Application of baicalein in preparation of medicine for treating human coronavirus 229E infected pneumonia

Abstract

The invention belongs to the technical field of medicines, and discloses application of baicalein in preparation of related medicines for treating human coronavirus 229E infected pneumonia. Specifically, the invention discloses application of baicalein in preparation of medicines playing a protective role in prevention and / or treatment of respiratory dysfunction, lung injury, inflammatory response, virus infection and immune disorder caused by human coronavirus 229E infected pneumonia. Pharmacological experiments prove that baicalein can improve the respiratory function in human coronavirus 229E infected pneumonia, exert anti-inflammatory, anti-virus and immunoregulation effects, and can improve pulmonary edema, thereby achieving the purpose of treatment.

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to the use of baicalein in preparing a medicament for preventing and / or treating pneumonia infected by human coronavirus 229E. Background Art

[0002] Coronaviruses can cause respiratory, neuronal, and intestinal infections in animals and humans [1-2] . To date, seven coronaviruses are known to infect humans and cause respiratory diseases of varying severity, ranging from the common cold to severe pneumonia, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The latter three are zoonotic, highly pathogenic, and have caused or are causing outbreaks, epidemics or pandemics. The other four coronaviruses, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1, circulate in the human population worldwide and cause about one-third of human common cold infections. [3-4] These four HCoVs occasionally cause life-threatening pneumonia and bronchiolitis in the elderly, children, and immunocompromised patients. [5-8] Although HCoV-229E is usually associated with the common cold, a small number of healthy adults infected with 229E may develop acute respiratory distress syndrome. [9] .

[0003] As a natural medicine, Scutellaria baicalensis has the effects of clearing heat and dampness, detoxifying, and stopping bleeding. It is widely used in the treatment of cardiovascular and cerebrovascular diseases, diabetes, neurodegenerative diseases and other diseases.

[10] Baicalein is a flavonoid component in Scutellaria baicalensis, which has multiple activities such as anti-inflammatory, antioxidant, immunomodulatory, antiviral, anti-apoptotic, and antibacterial.

[11] Xu et al. reported that baicalein can significantly reduce the mortality of mice caused by influenza A virus A / FM1 / 1 / 47 (H1N1), significantly reduce the replication rate of the virus, and significantly inhibit the growth of the virus, suggesting that baicalein has a significant inhibitory effect on influenza virus.

[12] Song et al. reported that baicalein can significantly reduce the damage of SARS-CoV-2 to Vero E6 cells, reduce the viral load in mouse lung tissue in a time-related and concentration-related manner, and alleviate lung tissue damage and inflammatory cell infiltration.

[13] According to existing reports, baicalin has a good therapeutic effect on pneumonia caused by viruses (including influenza virus, coronavirus, etc.), but no research has been found on the therapeutic effect of baicalin on pneumonia infected by human coronavirus 229E.

[0004] In Chinese patent CN116920094A, Inner Mongolia Medical University provides the application of Burunag for the treatment of pneumonia infected with human coronavirus 229E.

[14] In Chinese patent CN113940942A, Beijing Yingke Rui Drug Safety and Efficacy Research Co., Ltd. disclosed the application of baicalin in treating coronavirus infectious diseases, and verified the new application of baicalin in in vitro cell experiments and mouse experiments infected with human coronavirus HCoV-229E.

[15] In Chinese patents CN114073676A and CN114081892A, Hainan Star Pharmaceutical Co., Ltd. disclosed the use of diammonium glycyrrhizinate and its inhalation preparation and polydatin in the preparation of drugs for treating coronavirus infectious diseases. The new application of diammonium glycyrrhizinate and polydatin was verified in a mouse experiment infected with human coronavirus HCoV-229E. [16-17] In Chinese patent CN114159442A, Yingke Rui (Tianjin) Innovation Pharmaceutical Research Co., Ltd. disclosed the application of Favipiravir in treating coronavirus infectious diseases. The new application and effective dosage range of Favipiravir were verified in mice infected with human coronavirus HCoV-229E.

[18] In Chinese patent CN113967211B, Shandong Dayin Marine Biopharmaceutical Co., Ltd. disclosed the use of lycorine hydrochloride thioester in the preparation of anti-coronavirus drugs, and verified it in a mouse experiment infected with human coronavirus HCoV-229E.

[19] In Chinese patents CN114146082A, CN114146078A, CN114073685A and CN114073686A, the use of methyl parahydroxybenzoate and its sodium salt, ethyl parahydroxybenzoate, cresol and m-cresol for preparing drugs for treating viral infectious diseases is disclosed, and the therapeutic effect on pneumonia mice caused by human coronavirus HCoV-229E is verified. [20-23] In Chinese patent CN114053272A, Yingke Rui (Tianjin) Innovation Pharmaceutical Research Co., Ltd. discloses the use of matrine and its inhalation preparation in the treatment of coronavirus infectious diseases.

[24] .

[0005] The aforementioned patents involve compounds currently prepared for the prevention and / or treatment of pneumonia caused by human coronavirus 229E, which are fundamentally different from the baicalein described herein. Baicalein's various pharmacological effects, including anti-inflammatory, antioxidant, immunomodulatory, antiviral, and anti-apoptotic properties, are closely related to the pathophysiological manifestations of viral pneumonia. Therefore, by examining relevant indicators, baicalein has been found to have therapeutic effects on pneumonia caused by human coronavirus 229E. In summary, to date, no research has been reported on the therapeutic effects of baicalein on pneumonia caused by human coronavirus 229E. In light of this, the present invention is proposed. Summary of the Invention

[0006] The technical problem to be solved by the present invention is to provide a new use of baicalein in the preparation of a drug for preventing and / or treating pneumonia infected with human coronavirus 229E.

[0007] The present invention achieves the purpose of the invention through the following technical solutions:

[0008] One of the purposes of the present invention is to provide the use of baicalein in drugs and other products related to the treatment of pneumonia infected with human coronavirus 229E.

[0009] The second purpose of the present invention is to provide the use of baicalein in treating symptoms such as inflammatory response, immune disorder, viral infection, and abnormal respiratory function caused by pneumonia infected with human coronavirus 229E.

[0010] The third purpose of the present invention: The baicalein described in the present invention can effectively restore the increase in respiratory rate (F) and minute ventilation (MV) and the decrease in peak expiratory flow (PEF) and enhanced pause (PenH) caused by pneumonia infected with human coronavirus 229E, thereby improving respiratory function.

[0011] The fourth object of the present invention: The baicalein described in the present invention achieves anti-inflammatory effects by reducing the number of white blood cells (WBC) and neutrophils (NEUT) in the blood, and reducing the levels of interleukin-1β (IL-1β), interleukin-10 (IL-10), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) in the serum.

[0012] The fifth purpose of the present invention: The baicalein described in the present invention can reduce the lung index, restore the alveolar state of damaged lung tissue, and achieve lung tissue repair.

[0013] The sixth purpose of the present invention: The baicalein described in the present invention can reduce the viral load in lung tissue and achieve an antiviral effect.

[0014] The seventh purpose of the present invention: The baicalein described in the present invention can reduce the number of lymphocytes (LYM) in the blood, adjust the spleen index and thymus index, increase the CD4 / CD8 value and the number of antigen presenting cells (APC), and achieve an immunomodulatory effect.

[0015] In order to solve the technical problems of the present invention, the present invention provides the following technical solutions:

[0016] Male Balb / c mice were infected intranasally with HCoV-229E virus solution to establish a human coronavirus 229E pneumonia model. Two infections were performed on the first and third days. Drug administration began on the first day of infection. During drug administration, mice were weighed and blood samples were collected daily for routine blood tests. Respiratory function was measured on the second and fourth days of the experiment. After four days of drug treatment, blood samples were collected to obtain serum for inflammatory cytokine levels. The lungs, spleen, and thymus were weighed and weighed to calculate organ indices. Partial lung tissue was collected for viral nucleic acid load determination. Flow cytometry was used to determine the percentage of splenic lymphocytes. The therapeutic effect of baicalin on human coronavirus 229E pneumonia was evaluated.

[0017] The present invention also relates to pharmaceutical compositions of the compounds of the present invention and conventional pharmaceutical excipients or adjuvants.

[0018] The compounds of this invention can be prepared according to methods well known in the art. When used for this purpose, if necessary, the compounds of this invention can be combined with one or more solid or liquid pharmaceutical excipients and / or adjuvants to prepare suitable administration forms or dosage forms that can be used as human or veterinary medicines.

[0019] The compound of the present invention or the pharmaceutical composition containing the same can be administered in a unit dosage form, and the administration route can be enteral or parenteral, such as oral, intramuscular, subcutaneous, nasal, oral mucosa, skin, peritoneum or rectum.

[0020] The compound of the present invention or the pharmaceutical composition containing the same can be administered by injection, including intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection and acupuncture injection.

[0021] The dosage form can be a liquid or solid dosage form. For example, liquid dosage forms can be true solutions, colloids, microparticles, emulsions, or suspensions. Other dosage forms include tablets, capsules, pellets, aerosols, pills, powders, solutions, suspensions, emulsions, granules, suppositories, and freeze-dried powder injections.

[0022] The compound of the present invention can be prepared into common preparations, sustained-release preparations, controlled-release preparations, targeted preparations and various microparticle delivery systems.

[0023] Beneficial Technical Effects: This compound has outstanding pharmacological activity, effectively restoring the increased respiratory rate and minute ventilation, as well as the decreased peak expiratory flow and enhanced expiratory interval, caused by pneumonia caused by human coronavirus 229E infection. It also reduces the number of white blood cells, lymphocytes, and neutrophils in the blood, lowers serum levels of IL-1β, IL-10, IL-6, and TNF-α, reduces the lung index, increases the spleen index and thymus index, reduces the viral load in lung tissue, and increases the CD4 / CD8 ratio and APC count. This compound achieves synergistic effects of improving respiratory function, anti-inflammatory and antiviral effects, repairing lung tissue, and immunomodulating. It is suitable for use in the treatment of pneumonia caused by human coronavirus 229E. This compound has high safety, a reliable ingredient source, and low production costs, and has promising market development prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 Effects of baicalein on respiratory function in mice with pneumonia infected with human coronavirus 229E;

[0025] Figure 2 Effects of baicalein on routine blood tests in mice with pneumonia infected with human coronavirus 229E;

[0026] Figure 3 Effects of baicalin on organ indices in mice with pneumonia infected with human coronavirus 229E;

[0027] Figure 4 Effects of baicalein on serum inflammatory factors in mice with pneumonia infected with human coronavirus 229E;

[0028] Figure 5 Effect of baicalein on the viral load in lung tissue of mice with pneumonia infected with human coronavirus 229E;

[0029] Figure 6 Effects of baicalein on splenic lymphocytes in mice with pneumonia infected with human coronavirus 229E. Figure 7 Effects of baicalein on damaged lung tissue in mice with pneumonia infected with human coronavirus 229E. DETAILED DESCRIPTION

[0030] In order to make the objectives, technical solutions and advantages of the present invention more clear, the present invention will be described in further detail below with reference to the accompanying drawings.

[0031] Table 1 Abbreviations

[0032]

[0033] Example 1

[0034] Effects of baicalein on respiratory function in mice with pneumonia infected with human coronavirus 229E

[0035] 1. Experimental Methods

[0036] Embodiment Animal selection male SPF grade Balb / c mice 40, body weight 12-14g, are randomly divided into 5 groups, 8 in every group, and above-mentioned 5 groups are respectively set as normal control group, model group, baicalein low, medium and high three dosage groups (50mg / kg, 100mg / kg, 200mg / kg).Give corresponding dosage medicine with gavage mode, after modeling on the first day, namely start administration, and administer for four days.On the second day and the 4th day of modeling, 6 mice of each group adopt WBP whole body plethysmography system to measure respiratory function, after instrument calibration is zeroed, setting flow parameter is 0.3L / min, mice are put into adaptation 15min in advance, and then record 15min and be measured data.

[0037] 2. Experimental Results

[0038] Compared with the normal group mice, the F and minute ventilation MV of the model group mice increased significantly on the second and fourth days after modeling, while PEF and PenH decreased significantly, which was more significant on the fourth day ( # P<0.05, ## P<0.01, ### P<0.001). However, treatment with 200 mg / kg baicalein effectively reduced F and MV and significantly increased PEF. The effect on F was more significant on the fourth day, while the effect on PenH was not significant. Treatment with 100 mg / kg baicalein effectively reduced F and MV and significantly increased PEF. The effect on F was more significant on the fourth day, while PenH was significantly increased on the fourth day. Treatment with 50 mg / kg baicalein effectively reduced F and MV and significantly increased PEF. The effect on F and PEF was more significant on the fourth day, while PenH was significantly increased on the fourth day. * P<0.05, ** P<0.01, *** P < 0.001)( Figure 1 , Table 2).

[0039] Table 2 Effects of baicalein on respiratory function in mice with pneumonia infected with human coronavirus 229E (Mean±SD)

[0040]

[0041] Mean ± SD, n = 6; # P<0.05, ## P<0.01, ### P<0.001 vs normal group, * P<0.05, ** P<0.01 *** P<0.001 vs model group

[0042] Example 2

[0043] Effects of baicalein on routine blood parameters in mice with pneumonia infected with human coronavirus 229E

[0044] 1. Experimental Methods

[0045] Examples Animals 40 male SPF Balb / c mice weighing 12-14 g were randomly divided into five groups of eight mice each. The five groups were set as a normal control group, a model group, and three baicalein low-, medium-, and high-dose groups (50 mg / kg, 100 mg / kg, and 200 mg / kg). The corresponding doses of drugs were administered by gavage. Dosing began on the first day after modeling. For four days, 20 μL of blood was collected four hours after dosing every day for five consecutive days and tested using a five-type blood cell counter.

[0046] 2. Experimental Results

[0047] Compared with the normal group, the number of white blood cells, lymphocytes and neutrophils in the model group increased significantly, which was more significant from the second to the fourth day. There was no significant change in the platelet content ( # P<0.05, ## P<0.01, ### P<0.001). Treatment with 200 mg / kg baicalein significantly reduced the number of white blood cells and neutrophils on the second to fourth day, which was more obvious on the second and fourth day. It significantly reduced the number of lymphocytes on the second to fifth day. The effect on reducing the number of white blood cells and neutrophils on the first day was not obvious. Treatment with 50 and 100 mg / kg baicalein significantly reduced the number of white blood cells, lymphocytes and neutrophils on the second to fourth day. The effect on reducing the number of lymphocytes on the fifth day was more obvious on the second and fourth day. The effect on reducing the number of white blood cells and neutrophils on the first day was not obvious. The effect of 100 mg / kg baicalein was better ( * P<0.05, ** P<0.01, *** P < 0.001)( Figure 2 , Table 3).

[0048] Table 3 Effects of baicalein on blood routine indicators in mice with pneumonia infected with human coronavirus 229E (Mean±SD)

[0049]

[0050] Mean±SD,n=6, # P<0.05, ## P<0.01, ### P<0.001vs normal group, * P<0.05,** P<0.01 *** P

[0051] <0.001vs model group

[0052] Example 3

[0053] Effects of baicalein on organ indices in mice with pneumonia infected with human coronavirus 229E

[0054] 1. Experimental Methods

[0055] Examples: Forty male SPF Balb / c mice weighing 12-14 g were randomly divided into five groups of eight mice each. The five groups were designated as a normal control group, a model group, and three baicalein low-, medium-, and high-dose groups (50 mg / kg, 100 mg / kg, and 200 mg / kg). The corresponding doses of drug were administered by gavage, starting on the first day after modeling. Dosing continued for four days and on the fifth day, the mice were weighed. Blood samples were collected, and the lungs, spleen, and thymus were washed with physiological saline to remove excess blood. Excess water was then removed using filter paper. The weights were then weighed and calculated as organ weights. Organ index (%) = organ weight (g) / body weight (g) × 100%.

[0056] 2. Experimental Results

[0057] Compared with the normal group, the lung index of the model group mice increased significantly, and the thymus and spleen indexes decreased significantly ( # P<0.05, ## P<0.01, ### P<0.001). Treatment with 200 mg / kg baicalein significantly increased the thymus index and spleen index, but had no significant effect on reducing the lung index; treatment with 100 mg / kg baicalein significantly reduced the lung index and significantly increased the thymus and spleen indexes; treatment with 50 mg / kg baicalein had the most significant effect on reducing the lung index and significantly increased the spleen index, but had no significant effect on the thymus index ( * P<0.05, ** P<0.01, *** P < 0.001)( Figure 3 , Table 4).

[0058] Table 4 Effects of baicalein on organ indexes of mice infected with pneumonia caused by human coronavirus 229E (Mean±SD)

[0059]

[0060] Mean±SD,n=8, ## P<0.01, ### P<0.001vs normal group, * P<0.05,** P<0.01 *** P<0.001 vs model group

[0061] Example 4

[0062] Effects of baicalein on serum inflammatory factors in mice with pneumonia infected with human coronavirus 229E

[0063] 1. Experimental Methods

[0064] Embodiment Animal selection Male SPF grade Balb / c mice 40, body weight 12-14g, were randomly divided into 5 groups, 8 in each group, and the above 5 groups were set as normal control group, model group, baicalein low, medium and high three dosage groups (50mg / kg, 100mg / kg, 200mg / kg). The corresponding dose of medicine was given by gavage, and the drug was started after modeling on the first day. Blood was collected for four days. The blood was loaded into 1.5mL EP tubes, placed at room temperature for 2h, put into 4℃ pre-cooled low-temperature centrifuges, and centrifuged at 3000rpm for 15min. The serum was divided into EP tubes and stored at -80℃ to be tested. The content of inflammatory factors in serum was detected using ultrasensitive multifactor electrochemiluminescence technology.

[0065] 2. Experimental Results

[0066] Compared with the normal group, the serum levels of TNF-α, IL-6, IL-10 and IL-1β in the model group were significantly increased ( # P<0.05, ## P<0.01, ### P<0.001). Baicalein at all doses significantly reduced the levels of IL-1β and TNF-α, with 100 mg / kg of baicalein having the best effect. Baicalein at 50 and 100 mg / kg significantly reduced the level of IL-10. Baicalein at 100 mg / kg also significantly reduced the level of IL-6 ( * P<0.05, ** P<0.01, *** P < 0.001)( Figure 4 , Table 5).

[0067] Table 5 Effect of baicalein on serum inflammatory factors in mice with pneumonia infected with human coronavirus 229E (Mean±SD)

[0068]

[0069] Mean±SD,n=8, # P<0.05, ## P<0.01, ### P<0.001 vs normal group, * P<0.05,** P<0.01 *** P<0.001 vs model group

[0070] Example 5

[0071] Effect of baicalein on viral load in lung tissue of mice with pneumonia infected with human coronavirus 229E

[0072] 1. Experimental Methods

[0073] Example Animal Selection Male SPF grade Balb / c mice 40, weighing 12-14g, were randomly divided into 5 groups of 8 each. The above 5 groups were set as normal control group, model group, and baicalein low, medium and high dose groups (50mg / kg, 100mg / kg, 200mg / kg). The corresponding dose of the drug was given by gavage. After modeling on the first day, the drug was started. After four days of administration, the lung tissue was taken and subpackaged and stored at -80°C. 5mg of lung tissue was ground and RNA was extracted. The lung tissue viral nucleic acid load was determined according to the human coronavirus 229E fluorescent quantitative RT-PCR detection kit.

[0074] 2. Experimental Results

[0075] Compared with the normal group mice, the viral load in the lung tissue of the model group mice was significantly increased ( ### P<0.001). The viral load in lung tissue of each baicalein treatment group was significantly decreased ( * P<0.05, ** P < 0.01)( Figure 5 , Table 6).

[0076] Table 6 Effect of baicalein on the viral load in lung tissue of mice infected with human coronavirus 229E pneumonia (Mean±SD)

[0077]

[0078] Mean±SD,n=3, ## P<0.01 vs normal group, * P<0.05 vs model group

[0079] Example 6

[0080] Effects of baicalein on splenic lymphocytes in mice with pneumonia infected with human coronavirus 229E

[0081] 1. Experimental Methods

[0082] Embodiment Animal selection Male SPF grade Balb / c mice 40, body weight 12-14g, are randomly divided into 5 groups, 8 in each group, and above-mentioned 5 groups are respectively set as normal control group, model group, baicalein low, medium and high three dosage groups (50mg / kg, 100mg / kg, 200mg / kg).Give corresponding dosage medicine by gavage, i.e. start administration after modeling on the first day, administer for four days, take spleen and add 1640 culture medium grinding centrifugation (3000rpm, 10min) to obtain splenocytes, add red blood cell lysis buffer fully lysing after resuspending and centrifuge (3000rpm, 10min), precipitate is resuspended and centrifuged (3000rpm, 10min) with normal saline, repeat twice, add CD3, CD4, CD8 and CD19 antibody staining and use flow cytometer to detect spleen lymphocytes.

[0083] 2. Experimental Results

[0084] Compared with the normal group, the CD4 / CD8 value and APC number of the model group mice were significantly decreased ( # P<0.05). Treatment with baicalein at different doses significantly increased the CD4 / CD8 ratio and the number of APCs. (** P < 0.01)( Figure 6 , Table 7).

[0085] Table 7 Effect of baicalein on spleen lymphocytes of mice infected with pneumonia caused by human coronavirus 229E (Mean±SD)

[0086]

[0087] Mean±SD,n=3, # P<0.05vs normal group, * P<0.05, ** P<0.01 vs model group

[0088] Example 8

[0089] Effects of baicalein on damaged lung tissue in mice with pneumonia infected with human coronavirus 229E

[0090] 1. Experimental Methods

[0091] Examples Animals Forty male SPF Balb / c mice weighing 12-14 g were randomly divided into five groups of eight mice each. The five groups were set as a normal control group, a model group, and three baicalein low-, medium-, and high-dose groups (50 mg / kg, 100 mg / kg, and 200 mg / kg). The corresponding doses of drugs were administered by gavage. Dosing began on the first day after modeling. Dosing continued for four days. On the fifth day, the left lungs of each group of mice were dissected, fixed with fixative, dehydrated, embedded in paraffin, and sectioned for H&E staining.

[0092] 2. Experimental Results

[0093] By comparing the lung tissue sections after staining, compared with the control group, the model group had disordered alveolar structure, ruptured alveolar septa, dilated alveoli, and a significantly reduced number of alveoli, while the above pathological changes in the lung tissue of the mice in the baicalein intervention group were improved ( Figure 7 ).

[0094] References

[0095] [1]Phan MVT, Ngo Tri T, Hong Anh P, et al. Identification and characterization ofCoronaviridae genomes from Vietnamese bats and rats based on conserved proteindomains.Virus Evol.2018,4(2):vey035.

[0096] [2] Wu Y, Xu X, Chen Z, et al. Nervous systeminvolvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun. 2020,87:18-22.

[0097] [3]Van der Hoek L. Human coronaviruses: what do they cause? .AntivirTher.2007,12(4 Pt B):651-658.

[0098] [4]Davis BM,Foxman B,Monto AS,et al.Human coronaviruses and otherrespiratoryinfections in young adults on a university campus:Prevalence,symptoms,andshedding.Influenza Other Respir Viruses.2018,12(5):582-590.

[0099] [5]Pene F,Merlat A,Vabret A,et al.Coronavirus 229E-related pneumoniainimmunocompromised patients.Clin Infect Dis.2003,37(7):929-932.

[0100] [6]Walsh EE,Shin JH,Falsey AR.Clinical impact of human coronaviruses229E andOC43 infection in diverse adult populations.J Infect Dis.2013,208(10):1634-1642. [7]Gorse GJ,O'Connor TZ,Hall SL,et al.Human coronavirus and acuterespiratoryillness in older adults with chronic obstructive pulmonarydisease.J Infect Dis.2009,199(6):847-857.

[0101] [8]Cui J,Li F,Shi ZL.Origin and evolution of pathogeniccoronaviruses.Nat RevMicrobiol.2019,17(3):181-192.

[0102] [9]Vassilara F,Spyridaki A,Pothitos G,et al.ARare Case of HumanCoronavirus 229EAssociated with Acute Respiratory Distress Syndrome in aHealthy Adult.Case RepInfect Dis.2018,2018:6796839.

[0103]

[10] Yang X, Zheng S, Wang X, et al.Advances in pharmacology, biosynthesis, and metabolic engineering of Scutellariaspecialized metabolites [J].Crit Rev Biotechnol, 2022:1-17.

[0104]

[11] Zhao T,Tang H,Xie L,et al.Scutellaria baicalensis Georgi.(Lamiaceae):A reviewof its traditional uses,botany,phytochemistry,pharmacology and toxicology[J].JPharm Pharmacol,2019,71(9):1353-1369.

[0105] Biol PharmBull, 2010, 33(2):238-243

[12] Xu G, Dou J, Zhang L, et al.

[0106]

[13] Song JK,Zhang L,Xu YF,et al.Therapeutic effects of baicalein for the treatment of COVID-19 in vivo and invitro[J].BiochemPharmacol,2021,183:1

[0107]

[14] Online CN116920094A

[0108]

[15] Transfer CN113940942A

[0109]

[16] Additional number CN114073676A

[0110]

[17] Additional registration CN114081892A

[0111]

[18] Chinese patent CN114159442A

[0112]

[19] Chinese patent CN113967211B

[0113]

[20] Chinese patent CN114146082A

[0114]

[21] Chinese patent CN114146078A

[0115]

[22] Chinese patent CN114073685A

[0116]

[23] Chinese patent CN114073686A

[0117]

[24] Chinese patent CN114053272A.

Claims

1. Use of baicalein in the preparation of a drug for preventing and / or treating pneumonia caused by human coronavirus 229E infection, the structural formula of which is shown below:

2. The use according to claim 1, characterized in that Baicalein can achieve the therapeutic effect of pneumonia caused by human coronavirus 229E infection by improving respiratory function.

3. The use according to claim 2, characterized in that Baicalein effectively restores the increase in respiratory rate and minute ventilation and the decrease in peak expiratory flow and enhanced expiratory interval caused by human coronavirus 229E pneumonia, thereby improving respiratory function.

4. The use according to claim 1, characterized in that Baicalein can achieve the therapeutic effect of pneumonia infected with human coronavirus 229E through its anti-inflammatory effect.

5. The use according to claim 4, characterized in that Baicalein achieves its anti-inflammatory effect by reducing the number of white blood cells and neutrophils in the blood and lowering the levels of interleukin-1β, interleukin-10, interleukin-6, and tumor necrosis factor-α in the serum.

6. The use according to claim 1, characterized in that Baicalein can repair damaged lung tissue and reduce pulmonary edema, thereby achieving the therapeutic effect of pneumonia caused by human coronavirus 229E infection.

7. The use according to claim 6, characterized in that Baicalein can lower the lung index, restore the alveolar state of damaged lung tissue, and achieve lung tissue repair.

8. The use according to claim 1, characterized in that Baicalein achieves therapeutic effects on pneumonia caused by human coronavirus 229E through its antiviral effect.

9. The use according to claim 8, characterized in that Baicalein achieves its antiviral effect by reducing the viral load in lung tissue.

10. The use according to claim 1, characterized in that Baicalein achieves therapeutic effects on pneumonia caused by human coronavirus 229E through its immunomodulatory effect.

11. The use according to claim 10, characterized in that Baicalein achieves immunomodulatory effects by reducing the number of lymphocytes in the blood, adjusting the spleen index and thymus index, and increasing the CD4 / CD8 value and the number of antigen-presenting cells.

12. Use of a pharmaceutical composition for preventing and / or treating pneumonia caused by human coronavirus 229E infection, characterized in that: The pharmaceutical composition comprises the baicalein according to claim 1 and a pharmaceutically acceptable carrier or excipient.

13. Use according to claim 12, characterized in that The compound preparation dosage form is selected from: oral preparation, injection dosage form or skin mucosal route dosage form, oral preparation includes tablets, sustained-release preparations, capsules, controlled-release preparations, enteric solvents, pills or liquid preparations, and the injection dosage form includes intramuscular injection, intravenous injection or intravenous drip.

Images